Blockchain Registration Transaction Record
Late-Stage Biopharmaceutical Company Clene (NASDAQ: CLNN) Enters Securities Purchase Agreement
Clene Inc., a late clinical-stage biopharmaceutical company, has entered into a securities purchase agreement, issuing 742,626 shares of common stock for an estimated $7.3 million. The company is focused on developing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.
This news is important because it highlights a significant financial transaction for Clene Inc., a company dedicated to developing innovative therapies for neurodegenerative diseases. The agreement will provide the company with substantial gross proceeds, furthering its mission of improving mitochondrial health and protecting neuronal function.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0xa3ef03def55c700e3cfd7a83978f1f7e1361056f72f89e9dd785c9ee31d15506 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | keepwBne-5a82c40f0ad8cd45d742512c2de0e8d9 |